Academic Journal
Advanced delivery systems for sodium thiosulfate in cisplatin otoprotection.
| Τίτλος: | Advanced delivery systems for sodium thiosulfate in cisplatin otoprotection. |
|---|---|
| Συγγραφείς: | Dubashynskaya NV; Branch of Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute» - Institute of Macromolecular Compounds, Bolshoi VO 31, St. Petersburg 199004, Russia., Borovskoy AY; Branch of Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute» - Institute of Macromolecular Compounds, Bolshoi VO 31, St. Petersburg 199004, Russia., Zhuravskii SG; Almazov National Medical Research Centre, Akkuratova 2, St. Petersburg 197341, Russia; Pavlov First Saint Petersburg State Medical University, Lva Tolstogo 6-8, St. Petersburg 197022, Russia., Skorik YA; Branch of Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute» - Institute of Macromolecular Compounds, Bolshoi VO 31, St. Petersburg 199004, Russia. Electronic address: yury_skorik@mail.ru. |
| Πηγή: | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2026 Oct; Vol. 227, pp. 115183. Date of Electronic Publication: 2026 Jul 12. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3441 (Electronic) Linking ISSN: 09396411 NLM ISO Abbreviation: Eur J Pharm Biopharm Subsets: MEDLINE |
| Imprint Name(s): | Publication: Amsterdam : Elsevier Science Original Publication: Stuttgart : Wissenschaftliche Verlagsgesellschaft, c1991- |
| Ιατρικοί όροι (MeSH): | Thiosulfates*/administration & dosage , Thiosulfates*/pharmacokinetics , Cisplatin*/adverse effects , Cisplatin*/administration & dosage , Cisplatin*/pharmacokinetics , Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/administration & dosage , Drug Delivery Systems*/methods , Protective Agents*/administration & dosage , Hearing Loss, Sensorineural*/prevention & control , Hearing Loss, Sensorineural*/chemically induced, Nanoparticles/chemistry ; Humans ; Animals |
| Περίληψη: | Cisplatin is an indispensable agent in pediatric oncology, yet its clinical utility is severely compromised by irreversible sensorineural hearing loss, which affects up to 60 % of young patients. Sodium thiosulfate (STS) has recently emerged as the gold-standard otoprotectant, but its systemic administration is constrained by a critical pharmacokinetic paradox: a mandatory 6-hour delay after cisplatin infusion is required to avoid interference with antitumor efficacy, creating a window of vulnerability during which the inner ear remains unprotected. This review systematically examines the engineering strategies developed to overcome the limitations of systemic STS delivery, with a focus on nanotechnology platforms and localized routes of administration. We highlight how the shift from systemic to intratympanic delivery enables high intracochlear concentrations of STS without compromising the antineoplastic action of cisplatin. Key innovations include: (i) lipid- and polymer-based nanoparticle systems that optimize transport across the round window membrane; (ii) in situ-forming hydrogels and microgels that resist Eustachian tube clearance through bioadhesion and provide sustained STS release; and (iii) noninvasive transtympanic strategies that use chemical permeation enhancers to bypass the tympanic membrane, transfer through the walls of the tympanic cavity. The synergy of stimuli-responsive nanocarriers and localized delivery protocols represents a transformative approach to otoprotection, offering the prospect of hearing preservation precisely during peak cochlear cisplatin exposure and thereby improving the quality of life for childhood cancer survivors. (Copyright © 2026 Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: Cisplatin-induced ototoxicity; Intratympanic drug delivery; Otoprotection; Smartnanocarriers; Sodium thiosulfate; Thermosensitive hydrogels |
| Substance Nomenclature: | 0 (Thiosulfates) HX1032V43M (sodium thiosulfate) Q20Q21Q62J (Cisplatin) 0 (Antineoplastic Agents) 0 (Protective Agents) |
| Entry Date(s): | Date Created: 20260712 Date Completed: 20260831 Latest Revision: 20260831 |
| Update Code: | 20260901 |
| DOI: | 10.1016/j.ejpb.2026.115183 |
| PMID: | 42437593 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!